Literature DB >> 1434660

Primary gastrointestinal lymphomas in Turkey: a retrospective analysis of clinical features and results of treatment.

D Dinçol1, F Içli, S Erekul, N Günel, H Karaoğuz, A Demirkazik.   

Abstract

UNLABELLED: Thirty-three patients with primary gastrointestinal lymphoma (GIL) followed at Ankara University Medical School have been evaluated. The most frequent locations of the disease are the small intestine (48.4%) and the stomach (39.3%). The intermediate and high grade lymphomas constitute 84.8% of the cases. The mean age of the patients with small intestinal lymphoma is 28.7 years and 47.1 years for those with gastric lymphoma. The patients treated with surgery and chemotherapy (S+CT) have a longer survival than those treated with chemotherapy (CT) alone. IN
CONCLUSION: 1) Small intestinal lymphoma occurs more frequently than gastric lymphoma in our study. 2) The median age of the Turkish patients with primary GIL is approximately 10 years less than those in the Western countries. 3) The therapeutic results of S+CT are superior to those of CT in the early stages of the disease.

Entities:  

Mesh:

Year:  1992        PMID: 1434660     DOI: 10.1002/jso.2930510414

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

Review 1.  Primary gastric lymphoma.

Authors:  Ahmad M Al-Akwaa; Neelam Siddiqui; Ibrahim A Al-Mofleh
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

2.  Evaluation of 22 Primary Gastrointestinal Lymphoma Patients.

Authors:  Nilgun Yildirim; Mehmet Turkeli; Mehmet Naci Akdemir; Melih Simsek; Salim Basol Tekin
Journal:  Eurasian J Med       Date:  2019-02

3.  Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin's lymphomas in central Anatolia, in Turkey.

Authors:  Bulent Eser; Bunyamin Kaplan; Ali Unal; Ozlem Canoz; Fevzi Altuntas; H Ismail Sari; Ozlem Er; Metin Ozkan; Can Kucuk; Makbule Arar; Sebnem Gursoy; Mustafa Cetin
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.